"We want to outgrow the market, and we want to do it ethically." Christian Seufert, Head of Advanced Synthesis at Lonza and member of the executive committee, brings 20 years of experience from BASF's specialty chemical business. He leads a team applying 125 years of Lonza's chemistry expertise to manufacturing small molecules, highly potent APIs, and antibody-drug conjugates.In the latest PharmaSource podcast episode, Christian explains the ‘One Lonza’ strategy that positions the company to capture growth across the fastest-expanding CDMO segments, particularly bioconjugation, while addressing the industry's most persistent operational challenges: speed, data accessibility, and supply chain resilience.Read the full article

"Strategic partnerships — what a buzzword this has become in our industry." Kaan Fabian-Kekec and Clarita Havermeier at Simon-Kucher, unveiled exclusive new research at the start of CDMO Live Europe 2026.The research by Simon-Kucher and PharmaSource draws on 120+ senior executives across pharma and CDMOs globally. It reveals many areas of goal alignment, but highlights an execution gap as late-phase CDMOs are meeting established pharma's expectations just 44% of the time. The widest gaps are not quality or timelines. It's pricing and supply resilience.Listen to this recording from CDMO Live Europe 2026 and read the article

"A lot of biotech companies die because they run out of runway. And they might have been successful if they had another six or 12 months."Baruch Harris, Chief Operating Officer at Pretzel Therapeutics, has spent over two decades navigating the business side of life sciences, from consulting and big pharma to early-stage biotech. With a PhD in biochemistry and deep experience in business development, investor relations, and corporate strategy, he has been key in guiding Pretzel from seed stage through a $72.5 million Series A and subsequent Series B financing.In this episode of the PharmaSource podcast, Baruch shares the strategic decisions and creative financing structures that have kept Pretzel advancing its first-in-class mitochondrial biology pipeline, including a lead program currently wrapping up Phase 1 for rare mitochondrial depletion syndrome and an early-stage obesity asset. From spinout strategies to non-dilutive funding and the company's recent acquisition of Rome Therapeutics, his insights offer a practical roadmap for biotech leaders navigating today's capital-constrained environment.Read more.

"Sustainability should be understood as carbon, cost, and safety together. When a process becomes more efficient, you frequently improve all three."— Celine Chen, VP and Head of PharmaBlock EuropePharmaceutical sustainability is no longer a compliance exercise, but a commercial and strategic imperative. The greatest decarbonization opportunity does not just lie in renewable energy or facility upgrades, but inside the chemistry and process design of drug manufacturing itself, explains Celine Chen, VP and Head of PharmaBlock Europe, and David Ennis, Executive Advisor, PharmaBlock; Former VP Chemical Development, AstraZeneca. This episode of the PharmaSource explores why green chemistry must lead the pharmaceutical decarbonization agenda, what buyers should demand from CDMO partners, and how forward-thinking manufacturers are connecting carbon intelligence with process excellence.Read more.

"At Kindeva, we want to be viewed as a fully Annex 1 compliant facility and partner that can pivot when needed and supply uninterrupted to the patients that need it." Tommy Shornak, Senior Vice President of Sterile Injectables at Kindeva, brings nearly 20 years of sterile manufacturing operations experience from organizations including AMRI, Thermo Fisher Scientific, and Gilead Sciences. Since joining Kindeva in 2025, Tommy has been at the center of the company's investment strategy.In the latest PharmaSource podcast, Tommy explains why Kindeva's approach to sterile injectable CDMO services, anchored by a $200 million facility investment, a no-single-source supply policy, and a shift toward flexible commercial models, is designed to position the company as a one-stop partner for drug sponsors navigating an increasingly complex outsourcing landscape.Read more.

“The right CDMO is not the one with the biggest plant or the lowest price. It’s the one with the judgment, the systems, and the incentives to protect your molecule when complexity, scale, and scrutiny converge.”Alessio Piccoli, Chief Commercial Officer at PI Health Sciences (PIHS), a CDMO and CRO with discovery and process R&D capabilities in Jaipur and Hyderabad, India, and EU cGMP manufacturing in Lodi, Italy – a site holding FDA, AIFA, and KFDA approvals. The organization is backed by PI Industries, a global life sciences powerhouse with over 80 years of legacy in turning complex science into scalable real-world outcomes.In this episode of the PharmaSource podcast, Alessio explains why the most consequential differentiator in CDMO selection is control. He shares how PIHS is building a model defined by scientific accountability, digital execution, and a partnership mindset that links development decisions to commercial reality.Read more.

"If you feel the rules are changing every five minutes, that's not going to help you — because this is a long-term industry."Jan Ramakers is an independent consultant with over two decades of experience tracking the fine chemicals and pharmaceutical ingredients market. A chemist by training, Jan has worked across pharma, agrochemicals, and the financial sector, spanning market intelligence, competitor analysis, and M&A due diligence.In this PharmaSource podcast episode, Jan explains why the API outsourcing market is at an inflection point shaped by geopolitical uncertainty, supply chain fragility, and the evolving race among CDMOs to differentiate. Drawing on career-long pattern recognition, he outlines what is actually happening on the ground versus what the industry often gets wrong.Read more.

“A 10% success rate means you have to be smart about every decision you make in the pipeline.”Nick Wigdahl, Director of PharmaGro, has spent his career navigating two worlds that rarely talk to each other: the operational complexity of big pharma and the portfolio discipline of family office investing. That combination, he argues, is exactly what mid-size life science companies need more of.Nick Wigdahl is Director of PharmaGro, a consultancy specializing in CMC, supply chain, market assessment, and portfolio management for mid-size pharmaceutical and CDMO companies. His background includes supply chain leadership roles at Roche and GSK, as well as investment and portfolio management experience with family offices in logistics and transportation.In the latest PharmaSource podcast episode, Nick explains why managing molecule uncertainty is one of the most underappreciated disciplines in pharma, and how companies that get it right make better investment decisions, optimize their portfolios, and build more resilient businesses.Read full article

"The manufacturing process doesn't just produce the product — it determines what the product becomes." Stephen Sullivan, Founder of Linville Bio, brings more than two decades of experience spanning developmental biology, clinical translation, and manufacturing strategy across organizations, including Novartis and the Global Alliance for iPSC Therapies. Most recently, he led the setup of a first-in-human trial for an iPSC-based cancer vaccine.In this PharmaSource podcast episode, Stephen discusses the manufacturing challenges involved in induced pluripotent stem cell (iPSC) therapies and why companies that treat it as a downstream operational problem rather than a core product design decision are setting themselves up to fail.Read more.

"If I have one more person talk to me about agentic AI and then realize they're still using paper batch records, I'm going to scream." That frustration captures the central tension in CDMO digital transformation today says Matt Lowe, Chief Strategy Officer at MasterControl.Matt has spent nearly two decades at MasterControl, rising to CSO with responsibility spanning competitive intelligence, strategic partnerships, pricing, and product direction, making him one of the industry's sharpest observers of where life sciences manufacturing technology stands and the distance it still needs to travel.In the latest PharmaSource podcast episode, Matt maps the digital manufacturing journey contract development and manufacturing organizations (CDMOs) must take, from eliminating paper on the shop floor to achieving the industry's most coveted goal: golden batch and real-time release.Read more